HeatherAnnWakeleeMD

Clinical Trials

• Phase 2 Trial of Bevacizumab in Combination With Pemetrexed Start of enrollment: 2006 Mar 01

  Completed

  Phase 2

• Phase II Docetaxel / Carboplatin / XRT + Surgical Resection in Stage III NSCLC Start of enrollment: 2003 Mar 01

  Terminated

  Phase 2

• Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer Start of enrollment: 2006 Jun 01

  Completed

  Phase 2

• Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01

  Active, not recruiting

  Phase 3

• Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients Start of enrollment: 2007 Feb 01

  Completed

• Microarray Analysis of Gene Expression and Identification of Progenitor Cells in Lung Carcinoma Start of enrollment: 2002 Feb 01

  Terminated

• BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery Start of enrollment: 2011 Jan 17

  Completed

  Phase 2

• Phase I Vorinostat Concurrent With Stereotactic Radiosurgery (SRS) in Brain Metastases From Non-Small Cell Lung Cancer Start of enrollment: 2009 Jun 01

  Completed

  Phase 1

• 4D-CT-based Ventilation Imaging for Adaptive Functional Guidance in Radiotherapy Start of enrollment: 2009 Dec 01

  Terminated

  Early Phase 1

• Bevacizumab or Pemetrexed Disodium Alone or In Combination After Induction Therapy in Treating Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer Start of enrollment: 2010 Oct 25

  Completed

  Phase 3

• A Phase 2 Study of Amrubicin in Relapsed or Refractory Thymic Malignancies Start of enrollment: 2011 Jun 01

  Completed

  Phase 2

• Docetaxel, Cisplatin, and Cetuximab (TPC) in Palliative Treatment of Patients With Squamous Cell Carcinoma of the Head and Neck (SCCHN) Start of enrollment: 2011 Oct 01

  Completed

  Phase 2

• Phase 1 Erlotinib and Dovitinib (TKI258) in Advanced Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2012 Jul 01

  Terminated

  Phase 1

• Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer Start of enrollment: 2012 May 01

  Terminated

  Phase 1

• Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer Start of enrollment: 2012 Jun 01

  Completed

  Phase 1, Phase 2

• Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28

  Completed

  Phase 1, Phase 2

• Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC

  No longer available

• Phase 1 Trial of Hu5F9-G4, a CD47-targeting Antibody Start of enrollment: 2014 Aug 01

  Completed

  Phase 1

• Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities Start of enrollment: 2020 Dec 16

  Recruiting

  Phase 1, Phase 2

  Roles: Contact

• Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors Start of enrollment: 2018 Jun 25

  Recruiting

  Phase 2

  Roles: Principal Investigator, Contact

• Join now to see all